Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
The Vantage 2019 Preview looks at the risks and opportunities for the year ahead.
Following a sharp downturn in late 2018, the Pharma and Biotech sectors are entering 2019 in a state of uncertainty.
Investors are nervous, so are likely to become more cautious and selective in their choices. The potential upside of this could be a rallying M&A market as valuations drop, but data-led proof could be the key to attracting financing.